Oncolytics Biotech® Reports Updated Anal Cancer Data Showing Objective Response Rate More Than Double the Current Standard of Care

Oct 28, 2025, 07:30 ET Pelareorep plus atezolizumab achieves 30% ORR in second-line or later (≥2L) squamous cell anal carcinoma (SCAC) relative to 13.8% for the FDA-approved 2L treatment The median duration of response was 15.5 months compared to 9.5 months for the current standard of care Company expects to discuss single-arm accelerated approval study with FDA in Q1 2026 SAN DIEGO, Calif., Oct. 28, 2025 /PRNewswire/ — Oncolytics Biotech ® Inc. (NASDAQ: ONCY ) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced updated results from the single-arm squamous cell anal carcinoma (SCAC) cohort of the GOBLET study evaluating pelareorep in combination with atezolizumab (Tecentriq ® ) in patients with ≥2L metastatic SCAC. Patients from this cohort continue to be followed, and additional efficacy data are expected to be reported. The combination of pelareorep and atezolizumab achieved an objective response rate (ORR) of 30% (six among 20 evaluable patients). This represents a greater than 2x improvement over the historical benchmark of 13.8% ORR reported for the only FDA-approved immunotherapy for 2L SCAC. Importantly, there have been two durable complete responses among the six responders, with one ongoing beyond two years, and the other lasting 15 months. In addition, another patient has an ongoing response at 64 weeks. The overall median duration of response for patients receiving pelareorep and atezolizumab is 15.5 months compared to 9.5 months for the current standard of care at this stage of treatment. These updated results from this ongoing SCAC cohort reinforce the potential of pelareorep to drive durable immunologic tumor control in gastrointestinal tumors. The results also demonstrate the durability and depth of responses achievable with the combination of pelareorep and checkpoint inhibitors without chemotherapy. “This is the most encouraging efficacy signal with a non-chemo regimen we have ever seen in anal cancer,” said Jared Kelly, Chief Executive Officer of Oncolytics Biotech. “Achieving a 30% objective response rate — more than double the benchmark of the only approved immunotherapy — along with multiple responses lasting more than a year, including two complete responses, underscores pelareorep’s ability to unlock deep and durable immune responses. We believe the data represent our best chance to obtain an accelerated approval in a rare disease with virtually no options outside of chemotherapy.” The SCAC cohort is part of Oncolytics’ broader GOBLET study, a Phase 1/2 trial evaluating pelareorep in combination with checkpoint inhibitors and standard therapies across multiple gastrointestinal cancer indications, including pancreatic, colorectal, and anal cancers. Based on these compelling data, Oncolytics intends to engage the U.S. Food and Drug Administration (FDA) to discuss a potential single-arm study designed for accelerated approval in second-line or later SCAC, with a potential launch date for such a study expected in the first half of 2026. About GOBLET The GOBLET ( G astrointestinal tum O rs exploring the treatment com B inations with the oncolytic reovirus pe L ar E orep and an T i-PD-L1) study is a phase 1/2 multiple indication study in advanced or metastatic gastrointestinal tumors. The study is being conducted at 17 centers in Germany and is being managed by AIO-Studien-gGmbH. The co-primary endpoints of the study are objective response rate (ORR) and/or disease control rate assessed at week 16 and safety. Key secondary and exploratory endpoints include additional efficacy assessments and evaluation of potential biomarkers. The study comprises five treatment groups: Pelareorep in combination with atezolizumab, gemcitabine, and nab-paclitaxel in 1 st line advanced/metastatic pancreatic cancer patients; Pelareorep in combination with atezolizumab in 1 st line MSI (microsatellite instability)-high metastatic colorectal cancer patients; Pelareorep in combination with atezolizumab and TAS-102 in 3 rd line metastatic colorectal cancer patients Pelareorep in combination with atezolizumab in 2 nd line advanced and unresectable anal cancer patients; and Pelareorep in combination with mFOLFIRINOX with and without atezolizumab in newly diagnosed metastatic PDAC patients. Any cohort meeting pre-specified efficacy criteria in Stage 1 may be advanced to Stage 2 and enroll additional patients. About AIO AIO-Studien-gGmbH (AIO) emerged from the study center of the medical oncology working group within the German Cancer Society (DKG). AIO operates with a non-profit purpose of promoting science and research with a focus on medical oncology. Since its foundation, AIO has become a successful sponsor and study management company and has established itself both nationally and internationally. About Oncolytics Biotech Inc. Oncolytics is a clinical-stage biotechnology company developing pelareorep, an investigational intravenously delivered double-stranded RNA immunotherapeutic agent. Pelareorep has demonstrated encouraging results in multiple first-line pancreatic cancer studies, two randomized Phase 2 studies in metastatic breast cancer, and early-phase studies in anal and colorectal cancer. It is designed to induce anti-cancer immune responses by converting immunologically “cold” tumors “hot” through the activation of innate and adaptive immune responses. The Company is advancing pelareorep in combination with chemotherapy and/or checkpoint inhibitors in metastatic pancreatic and breast cancers, of which both development programs have received Fast Track designation from the FDA, and other gastrointestinal tumors. Oncolytics is actively pursuing strategic partnerships to accelerate development and maximize commercial impact. For more about Oncolytics, please visit: www.ir.oncolyticsbiotech.com or follow the Company on social media on LinkedIn and on X @ oncolytics . Tecentriq ® (atezolizumab) is a registered trademark of Genentech, a member of the Roche Group. Forward-looking statements This press release contains forward-looking statements, within the meaning of Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as “forward-looking statements”). Forward-looking statements contained in this press release include statements regarding beliefs as to the potential, registration, mechanism of action and benefits of pelareorep as a cancer therapeutic; expectations regarding the outcome of an upcoming regulatory meeting, including in relation to the Company’s proposed design of potential pancreatic and anal cancer registration studies; expectations relating to outcomes of ongoing and future studies; Oncolytic s’ plan to continue actively pursuing strategic partnerships; its goals, strategies and objectives; and its belief in the clinical promise of pelareorep in metastatic pancreatic and other gastrointestinal cancers. In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. These statements involve known and unknown risks and uncertainties that may cause actual results to differ materially from those anticipated. These risks include, but are not limited to, regulatory outcomes, trial execution, financial resources, access to capital markets, and market dynamics. Please refer to Oncolytics’ public filings with securities regulators in the United States and Canada for more information. The Company assumes no obligation to update forward-looking statements, except as required by law. Company Contact Jon Patton Director of IR & Communication [email protected] Investor Relations for Oncolytics Mike Moyer LifeSci Advisors +1-617-308-4306 [email protected] Media Contact for Oncolytics Owen Blaschak LifeSci Communications [email protected] Logo: https://mma.prnewswire.com/media/2408622/5586029/Oncolytics_Biotech_Inc_Logo.jpg SOURCE Oncolytics Biotech® Inc. View All Press Releases 4350 Executive Drive Suite 325 San Diego, CA 92121 [email protected] Company Our Mission Leadership Board of Directors Careers Contact Science Our Science Pipeline Resources Investors Overview News Events Stock Information Filings Corporate Governance FAQs Privacy Policy Accessibility Cookie Policy Disclaimer Manage Consent Copyright © 2026 Oncolytics Biotech Inc. {"prefetch":[{"source":"document","where":{"and":[{"href_matches":"/*"},{"not":{"href_matches":["/wp-*.php","/wp-admin/*","/wp-content/uploads/*","/wp-content/*","/wp-content/plugins/*","/wp-content/themes/lsc-wp-theme-main/*","/wp-content/themes/astra/*","/*\\?(.+)"]}},{"not":{"selector_matches":"a[rel~=\"nofollow\"]"}},{"not":{"selector_matches":".no-prefetch, .no-prefetch a"}}]},"eagerness":"conservative"}]} <div class="wcc-consent-container wcc-hide" role="complementary"> <div class="wcc-consent-bar" data-tag="notice" style="background-color:#FFFFFF;border-color:#f4f4f4"> <div class="wcc-notice"> <p id="wcc-title" class="wcc-title" data-tag="title" role="heading" aria-level="1" aria-labelledby="wcc-title" style="color:#212121"></p><div class="wcc-notice-group"> <div id="wcc-notice-des" class="wcc-notice-des" data-tag="description" aria-describedby="wcc-notice-des" style="color:#212121"> <p>We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies. However you may visit Cookie Settings to provide a controlled consent.</p> </div><div class="wcc-notice-btn-wrapper" data-tag="notice-buttons"> <button class="wcc-btn wcc-btn-customize" aria-label="Customize" data-tag="settings-button" style="color:#001958;background-color:transparent">Customize</button> <button class="wcc-btn wcc-btn-reject" aria-label="Reject All" data-tag="reject-button" style="color:#001958;background-color:#8CC9E0;border-color:#8CC9E0">Reject All</button> <button class="wcc-btn wcc-btn-accept" aria-label="Accept All" data-tag="accept-button" style="color:#001958;background-color:#8CC9E0;border-color:#8CC9E0">Accept All</button> </div></div></div></div></div><div class="wcc-modal" role="dialog" aria-label="Privacy Overview"> <div class="wcc-preference-center" data-tag="detail" style="color:#212121;background-color:#FFFFFF;border-color:#f4f4f4"> <div class="wcc-preference-header"> <span id="wcc-preference-title" class="wcc-preference-title" data-tag="detail-title" role="heading" aria-level="1" aria-labelledby="wcc-preference-title" style="color:#212121">Privacy Overview</span> <button class="wcc-btn-close" aria-label="Close cookie preference modal" data-tag="detail-close"> <img src="https://ir.oncolyticsbiotech.com/wp-content/plugins/webtoffee-cookie-consent/lite/frontend/images/close.svg" alt="Close"> </button> </div><div class="wcc-preference-body-wrapper"> <div class="wcc-preference-content-wrapper" data-tag="detail-description" style="color:#212121"> <p>This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.</p> </div> <div class="wcc-google-privacy-policy" data-tag="google-privacy-policy"> </div><div class="wcc-accordion-wrapper" data-tag="detail-categories"> <div class="wcc-accordion" id="wccDetailCategorynecessary" role="button" aria-expanded="false"> <div class="wcc-accordion-item"> <div class="wcc-accordion-chevron"><i class="wcc-chevron-right"></i></div> <div class="wcc-accordion-header-wrapper"> <div class="wcc-accordion-header"><button class="wcc-accordion-btn" aria-label="Necessary" data-tag="detail-category-title" style="color:#212121">Necessary</button><span class="wcc-always-active">Always Active</span> <div class="wcc-switch" data-tag="detail-category-toggle"><input type="checkbox" id="wccSwitchnecessary"></div> </div> <div class="wcc-accordion-header-des" data-tag="detail-category-description" style="color:#212121"> <p>Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.</p></div> </div> </div> <div class="wcc-accordion-body" aria-hidden="true"> <div class="wcc-audit-table" data-tag="audit-table" style="color:#212121;background-color:#f4f4f4;border-color:#ebebeb"><ul class="wcc-cookie-des-table"><li><div>Cookie</div><div>wt_consent</div></li><li><div>Duration</div><div>1 year</div></li><li><div>Description</div><div>Used for remembering users’ consent preferences to be respected on subsequent site visits. It does not collect or store personal information about visitors to the site.</div></li></ul><ul class="wcc-cookie-des-table"><li><div>Cookie</div><div>_cfuvid</div></li><li><div>Duration</div><div>session</div></li><li><div>Description</div><div>Cloudflare sets this cookie to track users across sessions to optimize user experience by maintaining session consistency and providing personalized services</div></li></ul><ul class="wcc-cookie-des-table"><li><div>Cookie</div><div>rc::a</div></li><li><div>Duration</div><div>never</div></li><li><div>Description</div><div>This cookie is set by the Google recaptcha service to identify bots to protect the website against malicious spam attacks.</div></li></ul><ul class="wcc-cookie-des-table"><li><div>Cookie</div><div>rc::c</div></li><li><div>Duration</div><div>session</div></li><li><div>Description</div><div>This cookie is set by the Google recaptcha service to identify bots to protect the website against malicious spam attacks.</div></li></ul><ul class="wcc-cookie-des-table"><li><div>Cookie</div><div>__cf_bm</div></li><li><div>Duration</div><div>1 hour</div></li><li><div>Description</div><div>This cookie, set by Cloudflare, is used to support Cloudflare Bot Management. </div></li></ul></div> </div> </div><div class="wcc-accordion" id="wccDetailCategoryanalytics" role="button" aria-expanded="false"> <div class="wcc-accordion-item"> <div class="wcc-accordion-chevron"><i class="wcc-chevron-right"></i></div> <div class="wcc-accordion-header-wrapper"> <div class="wcc-accordion-header"><button class="wcc-accordion-btn" aria-label="Analytics" data-tag="detail-category-title" style="color:#212121">Analytics</button><span class="wcc-always-active">Always Active</span> <div class="wcc-switch" data-tag="detail-category-toggle"><input type="checkbox" id="wccSwitchanalytics"></div> </div> <div class="wcc-accordion-header-des" data-tag="detail-category-description" style="color:#212121"> <p>Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.</p></div> </div> </div> <div class="wcc-accordion-body" aria-hidden="true"> <div class="wcc-audit-table" data-tag="audit-table" style="color:#212121;background-color:#f4f4f4;border-color:#ebebeb"><ul class="wcc-cookie-des-table"><li><div>Cookie</div><div>_ga</div></li><li><div>Duration</div><div>1 year 1 month 4 days</div></li><li><div>Description</div><div>Google Analytics sets this cookie to calculate visitor, session and campaign data and track site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognise unique visitors.</div></li></ul><ul class="wcc-cookie-des-table"><li><div>Cookie</div><div>_gid</div></li><li><div>Duration</div><div>1 day</div></li><li><div>Description</div><div>Google Analytics sets this cookie to store information on how visitors use a website while also creating an analytics report of the website's performance. Some of the collected data includes the number of visitors, their source, and the pages they visit anonymously.</div></li></ul><ul class="wcc-cookie-des-table"><li><div>Cookie</div><div>_gat_gtag_UA_*</div></li><li><div>Duration</div><div>1 minute</div></li><li><div>Description</div><div>Google Analytics sets this cookie to store a unique user ID.</div></li></ul><ul class="wcc-cookie-des-table"><li><div>Cookie</div><div>_ga_*</div></li><li><div>Duration</div><div>1 year 1 month 4 days</div></li><li><div>Description</div><div>Google Analytics sets this cookie to store and count page views.</div></li></ul></div> </div> </div><div class="wcc-accordion" id="wccDetailCategoryperformance" role="button" aria-expanded="false"> <div class="wcc-accordion-item"> <div class="wcc-accordion-chevron"><i class="wcc-chevron-right"></i></div> <div class="wcc-accordion-header-wrapper"> <div class="wcc-accordion-header"><button class="wcc-accordion-btn" aria-label="Performance" data-tag="detail-category-title" style="color:#212121">Performance</button><span class="wcc-always-active">Always Active</span> <div class="wcc-switch" data-tag="detail-category-toggle"><input type="checkbox" id="wccSwitchperformance"></div> </div> <div class="wcc-accordion-header-des" data-tag="detail-category-description" style="color:#212121"> <p>Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.</p></div> </div> </div> <div class="wcc-accordion-body" aria-hidden="true"> <div class="wcc-audit-table" data-tag="audit-table" style="color:#212121;background-color:#f4f4f4;border-color:#ebebeb"><ul class="wcc-cookie-des-table"><li><div>Cookie</div><div>INGRESSCOOKIE</div></li><li><div>Duration</div><div>session</div></li><li><div>Description</div><div>This cookie is used for load balancing and session stickiness. This technical session identifier is required for some website features. </div></li></ul></div> </div> </div><div class="wcc-accordion" id="wccDetailCategoryadvertisement" role="button" aria-expanded="false"> <div class="wcc-accordion-item"> <div class="wcc-accordion-chevron"><i class="wcc-chevron-right"></i></div> <div class="wcc-accordion-header-wrapper"> <div class="wcc-accordion-header"><button class="wcc-accordion-btn" aria-label="Advertisement" data-tag="detail-category-title" style="color:#212121">Advertisement</button><span class="wcc-always-active">Always Active</span> <div class="wcc-switch" data-tag="detail-category-toggle"><input type="checkbox" id="wccSwitchadvertisement"></div> </div> <div class="wcc-accordion-header-des" data-tag="detail-category-description" style="color:#212121"> <p>Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.</p></div> </div> </div> <div class="wcc-accordion-body" aria-hidden="true"> <div class="wcc-audit-table" data-tag="audit-table" style="color:#212121;background-color:#f4f4f4;border-color:#ebebeb"><ul class="wcc-cookie-des-table"><li><div>Cookie</div><div>c</div></li><li><div>Duration</div><div>6 months 2 days</div></li><li><div>Description</div><div>Rubicon Project sets this cookie to control the synchronization of user identification and the exchange of user data between various ad services.</div></li></ul></div> </div> </div> </div></div><div class="wcc-footer-wrapper"> <span class="wcc-footer-shadow"></span> <div class="wcc-prefrence-btn-wrapper" data-tag="detail-buttons"> <button class="wcc-btn wcc-btn-reject" aria-label="Reject All" data-tag="detail-reject-button" style="color:#001958;background-color:#8CC9E0;border-color:#8CC9E0"> Reject All </button> <button class="wcc-btn wcc-btn-preferences" aria-label="Save My Preferences" data-tag="detail-save-button" style="color:#FFFFFF;background-color:#E8614D;border-color:#E8614D"> Save My Preferences </button> <button class="wcc-btn wcc-btn-accept" aria-label="Accept All" data-tag="detail-accept-button" style="color:#001958;background-color:#8CC9E0;border-color:#8CC9E0"> Accept All </button> </div><div style="padding: 8px 24px;font-size: 12px;font-weight: 400;line-height: 20px;text-align: right;border-radius: 0 0 6px 6px;direction: ltr;justify-content: flex-end;align-items: center;background-color:#EDEDED;color:#293C5B" data-tag="detail-powered-by"> Powered by <a target="_blank" rel="noopener" href="https://www.webtoffee.com/product/gdpr-cookie-consent" style="margin-left: 5px;line-height: 0"><img src="https://ir.oncolyticsbiotech.com/wp-content/plugins/webtoffee-cookie-consent/lite/frontend/images/webtoffee.svg" alt="Webtoffee logo" style="width: 78px;height: 13px;margin: 0"></a> </div></div></div></div><div class="wcc-overlay wcc-hide"></div> Secret Link ( () => { const lazyloadRunObserver = () => { const lazyloadBackgrounds = document.querySelectorAll( `.e-con.e-parent:not(.e-lazyloaded)` ); const lazyloadBackgroundObserver = new IntersectionObserver( ( entries ) => { entries.forEach( ( entry ) => { if ( entry.isIntersecting ) { let lazyloadBackground = entry.target; if( lazyloadBackground ) { lazyloadBackground.classList.add( 'e-lazyloaded' ); } lazyloadBackgroundObserver.unobserve( entry.target ); } }); }, { rootMargin: '200px 0px 200px 0px' } ); lazyloadBackgrounds.forEach( ( lazyloadBackground ) => { lazyloadBackgroundObserver.observe( lazyloadBackground ); } ); }; const events = [ 'DOMContentLoaded', 'elementor/lazyload/observe', ]; events.forEach( ( event ) => { document.addEventListener( event, lazyloadRunObserver ); } ); } )(); var astra = {"break_point":"1024","isRtl":"","is_scroll_to_id":"","is_scroll_to_top":"","is_header_footer_builder_active":"1","responsive_cart_click":"flyout","is_dark_palette":""}; //# sourceURL=astra-theme-js-js-extra jQuery.uiBackCompat = true; //# sourceURL=jquery-ui-core-js-before jQuery(function(jQuery){jQuery.datepicker.setDefaults({"closeText":"Close","currentText":"Today","monthNames":["January","February","March","April","May","June","July","August","September","October","November","December"],"monthNamesShort":["Jan","Feb","Mar","Apr","May","Jun","Jul","Aug","Sep","Oct","Nov","Dec"],"nextText":"Next","prevText":"Previous","dayNames":["Sunday","Monday","Tuesday","Wednesday","Thursday","Friday","Saturday"],"dayNamesShort":["Sun","Mon","Tue","Wed","Thu","Fri","Sat"],"dayNamesMin":["S","M","T","W","T","F","S"],"dateFormat":"MM d, yy","firstDay":1,"isRTL":false});}); //# sourceURL=jquery-ui-datepicker-js-after var astraAddon = {"is_elementor_active":"1","sticky_active":"1","svgIconClose":"\u003Cspan class=\"ast-icon icon-close\"\u003E\u003Csvg viewbox=\"0 0 512 512\" aria-hidden=\"true\" role=\"img\" version=\"1.1\" xmlns=\"http://www.w3.org/2000/svg\" xmlns:xlink=\"http://www.w3.org/1999/xlink\" width=\"18px\" height=\"18px\"\u003E\n \u003Cpath d=\"M71.029 71.029c9.373-9.372 24.569-9.372 33.942 0L256 222.059l151.029-151.03c9.373-9.372 24.569-9.372 33.942 0 9.372 9.373 9.372 24.569 0 33.942L289.941 256l151.03 151.029c9.372 9.373 9.372 24.569 0 33.942-9.373 9.372-24.569 9.372-33.942 0L256 289.941l-151.029 151.03c-9.373 9.372-24.569 9.372-33.942 0-9.372-9.373-9.372-24.569 0-33.942L222.059 256 71.029 104.971c-9.372-9.373-9.372-24.569 0-33.942z\" /\u003E\n \u003C/svg\u003E\u003C/span\u003E","hf_account_show_menu_on":"hover","hf_account_action_type":"link","hf_account_logout_action":"link","header_main_stick":"1","header_above_stick":"0","header_below_stick":"0","stick_header_meta":"","header_main_stick_meta":"","header_above_stick_meta":"","header_below_stick_meta":"","sticky_header_on_devices":"desktop","sticky_header_style":"none","sticky_hide_on_scroll":"1","break_point":"1024","tablet_break_point":"1024","mobile_break_point":"767","header_main_shrink":"","header_animation_effect":"none","header_logo_width":"","responsive_header_logo_width":{"desktop":180,"tablet":"","mobile":"","desktop-svg-height":42},"stick_origin_position":"","site_layout":"","site_content_width":"1680","site_layout_padded_width":"1200","site_layout_box_width":"1200","header_builder_active":"1","component_limit":"10","is_header_builder_active":"1"}; //# sourceURL=astra-addon-js-js-extra var elementorFrontendConfig = {"environmentMode":{"edit":false,"wpPreview":false,"isScriptDebug":false},"i18n":{"shareOnFacebook":"Share on Facebook","shareOnX":"Share on X","pinIt":"Pin it","download":"Download","downloadImage":"Download image","fullscreen":"Fullscreen","zoom":"Zoom","share":"Share","playVideo":"Play Video","previous":"Previous","next":"Next","close":"Close","a11yCarouselPrevSlideMessage":"Previous slide","a11yCarouselNextSlideMessage":"Next slide","a11yCarouselFirstSlideMessage":"This is the first slide","a11yCarouselLastSlideMessage":"This is the last slide","a11yCarouselPaginationBulletMessage":"Go to slide"},"is_rtl":false,"breakpoints":{"xs":0,"sm":480,"md":521,"lg":1025,"xl":1440,"xxl":1600},"responsive":{"breakpoints":{"mobile":{"label":"Mobile Portrait","value":520,"default_value":767,"direction":"max","is_enabled":true},"mobile_extra":{"label":"Mobile Landscape","value":880,"default_value":880,"direction":"max","is_enabled":false},"tablet":{"label":"Tablet Portrait","value":1024,"default_value":1024,"direction":"max","is_enabled":true},"tablet_extra":{"label":"Tablet Landscape","value":1200,"default_value":1200,"direction":"max","is_enabled":true},"laptop":{"label":"Laptop","value":1366,"default_value":1366,"direction":"max","is_enabled":true},"widescreen":{"label":"Widescreen","value":1901,"default_value":2400,"direction":"min","is_enabled":true}},"hasCustomBreakpoints":true},"version":"4.2.3","is_static":false,"experimentalFeatures":{"additional_custom_breakpoints":true,"container":true,"e_panel_promotions":true,"nested-elements":true,"global_classes_should_enforce_capabilities":true,"e_variables":true,"e_opt_in_v4_page":true,"e_components":true,"e_interactions":true,"e_widget_creation":true,"import-export-customization":true,"e_pro_atomic_form":true,"e_pro_collection_loop":true,"e_pro_variables":true,"e_pro_interactions":true},"urls":{"assets":"https:\/\/ir.oncolyticsbiotech.com\/wp-content\/plugins\/elementor\/assets\/","ajaxurl":"https:\/\/ir.oncolyticsbiotech.com\/wp-admin\/admin-ajax.php","uploadUrl":"https:\/\/ir.oncolyticsbiotech.com\/wp-content\/uploads"},"nonces":{"floatingButtonsClickTracking":"3b1c5706b7","atomicFormsSendForm":"b73be6a22b"},"swiperClass":"swiper","settings":{"page":[],"editorPreferences":[]},"kit":{"active_breakpoints":["viewport_mobile","viewport_tablet","viewport_tablet_extra","viewport_laptop","viewport_widescreen"],"viewport_widescreen":1901,"viewport_mobile":520,"global_image_lightbox":"yes","lightbox_enable_counter":"yes","lightbox_enable_fullscreen":"yes","lightbox_enable_zoom":"yes","lightbox_enable_share":"yes","lightbox_title_src":"title","lightbox_description_src":"description"},"post":{"id":7096,"title":"Oncolytics%20Biotech%C2%AE%20Reports%20Updated%20Anal%20Cancer%20Data%20Showing%20Objective%20Response%20Rate%20More%20Than%20Double%20the%20Current%20Standard%20of%20Care%20%7C%20Oncolytics%20Biotech%20Inc.","excerpt":"","featuredImage":false}}; //# sourceURL=elementor-frontend-js-before wp.i18n.setLocaleData( { 'text direction\u0004ltr': [ 'ltr' ] } ); //# sourceURL=wp-i18n-js-after var ElementorProFrontendConfig = {"ajaxurl":"https:\/\/ir.oncolyticsbiotech.com\/wp-admin\/admin-ajax.php","nonce":"60819fe108","urls":{"assets":"https:\/\/ir.oncolyticsbiotech.com\/wp-content\/plugins\/elementor-pro\/assets\/","rest":"https:\/\/ir.oncolyticsbiotech.com\/wp-json\/"},"settings":{"lazy_load_background_images":true},"popup":{"hasPopUps":false},"shareButtonsNetworks":{"facebook":{"title":"Facebook","has_counter":true},"twitter":{"title":"Twitter"},"linkedin":{"title":"LinkedIn","has_counter":true},"pinterest":{"title":"Pinterest","has_counter":true},"reddit":{"title":"Reddit","has_counter":true},"vk":{"title":"VK","has_counter":true},"odnoklassniki":{"title":"OK","has_counter":true},"tumblr":{"title":"Tumblr"},"digg":{"title":"Digg"},"skype":{"title":"Skype"},"stumbleupon":{"title":"StumbleUpon","has_counter":true},"mix":{"title":"Mix"},"telegram":{"title":"Telegram"},"pocket":{"title":"Pocket","has_counter":true},"xing":{"title":"XING","has_counter":true},"whatsapp":{"title":"WhatsApp"},"email":{"title":"Email"},"print":{"title":"Print"},"x-twitter":{"title":"X"},"threads":{"title":"Threads"}},"facebook_sdk":{"lang":"en_US","app_id":""},"lottie":{"defaultAnimationUrl":"https:\/\/ir.oncolyticsbiotech.com\/wp-content\/plugins\/elementor-pro\/modules\/lottie\/assets\/animations\/default.json"}}; //# sourceURL=elementor-pro-frontend-js-before /(trident|msie)/i.test(navigator.userAgent)&&document.getElementById&&window.addEventListener&&window.addEventListener("hashchange",function(){var t,e=location.hash.substring(1);/^[A-z0-9_-]+$/.test(e)&&(t=document.getElementById(e))&&(/^(?:a|select|input|button|textarea)$/i.test(t.tagName)||(t.tabIndex=-1),t.focus())},!1);

The release as fetched from its publisher. oncolyticsbiotech.com ↗